The molecular biology research on sulforaphane and cancer stem cell self-renewal is not in dispute. It is published, peer-reviewed, and produced at institutions including Johns Hopkins, MIT, and the National Cancer Institute. The mechanism is documented. Sulforaphane acts as an HDAC inhibitor — working at the epigenetic level to interrupt the gene expression that governs whether dormant cancer stem cells remain dormant or begin to self-renew.
You found that research. You acted on it. You were right to.
The problem is that sulforaphane does not exist preformed in broccoli or in most supplements. It has to be created through a conversion reaction between a precursor compound called glucoraphanin and an enzyme called myrosinase. That conversion requires intact plant tissue, functioning gut bacteria, and stomach conditions that most post-treatment patients no longer have.
You were targeting the right compound. You were being failed by the gap between what you consumed and what actually arrived at the cellular level in active form.
Every standard sulforaphane format depends on a conversion your post-treatment biology cannot reliably complete. That is not your failure. That is a delivery problem.



